Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

被引：0
作者：
Rogério Serafim Parra
Júlio Maria Fonseca Chebli
Natália Sousa Freitas Queiroz
Aderson Omar Mourão Cintra Damião
Matheus Freitas Cardoso de Azevedo
Liliana Andrade Chebli
Erika Ruback Bertges
Antonio José Tiburcio Alves Junior
Orlando Ambrogini Junior
Bianca Loyo Pona Schiavetti da Silva
Marcio Lubini
Mauro Bafutto
Cristina Flores
Eduardo Garcia Vilela
Sandra Felice Boratto
Newton Luiz Tricarico Gasparetti Junior
Flavio Steinwurz
Nayara Salgado Carvalho
Omar Féres
José Joaquim Ribeiro da Rocha
机构：
[1] University of São Paulo,Department of Surgery and Anatomy, Ribeirão Preto Medical School
[2] Federal University of Juiz de Fora,undefined
[3] Universidade de São Paulo,undefined
[4] Pontifícia Universidade Católica,undefined
[5] Federal University of São Paulo,undefined
[6] Prefeitura Municipal de Santos,undefined
[7] Passo Fundo University,undefined
[8] Federal University of Goiás,undefined
[9] Federal University of Rio Grande do Sul,undefined
[10] Federal University of Minas Gerais,undefined
[11] Centro Universitário Saúde ABC,undefined
[12] Hospital Vivalle Rede D’Or,undefined
[13] Hospital Israelita Albert Einstein,undefined
来源：
BMC Gastroenterology | / 22卷
关键词：
Ustekinumab; Crohn’s disease; Inflammatory bowel disease; Biological therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 187 条
[1]  
Roda G(2020)Crohn’s disease Nat Rev Dis Primers 6 22-1572
[2]  
Chien Ng S(2020)Infliximab-induced remission improves physical activity in patients with active Crohn's disease Rev Assoc Med Bras (1992) 66 1566-5882
[3]  
Kotze PG(2019)Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil World J Gastroenterol 25 5862-2934
[4]  
Argollo M(2020)Prevalence, indirect costs, and risk factors for work disability in patients with Crohn’s disease at a tertiary care center in Rio de Janeiro Dig Dis Sci 66 2925-223
[5]  
Panaccione R(2021)Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil World J Gastroenterol 27 208-427
[6]  
Spinelli A(2020)Inflammatory bowel disease care in Brazil: how it is performed, obstacles and demands from physicians' perspective Arq Gastroenterol 57 416-429
[7]  
Lucca FA(2018)Inflammatory bowel disease epidemiology in São Paulo State, Brazil Clin Exp Gastroenterol 11 423-417
[8]  
Malaguti C(2020)Impact of therapies on bowel damage in Crohn’s disease United Eur Gastroenterol J 8 410-26
[9]  
Chebli LA(2020)TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user's guide: an update Digestion 101 16-554
[10]  
Reboredo MM(2017)Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease J Gastroenterol 52 535-855
12345678910